Diplomat to Dispense KISQALI® for Metastatic Breast Cancer


The nation's largest independent specialty pharmacy will dispense KISQALI® (ribociclib) in combination with an aromatase inhibitor.

FLINT, Mich., March 16, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), will dispense KISQALI® (ribociclib) as a first-line treatment for postmenopausal women with a serious form of breast cancer.

The Food and Drug Administration recently approved KISQALI® as a once-daily oral therapy for use in combination with an aromatase inhibitor. It is for postmenopausal women who have advanced or metastatic breast cancer that is hormone receptor–positive and human epidermal growth factor receptor 2–negative.

To learn more about Diplomat's oncology program, visit diplomat.is/areas-of-excellence/oncology.

"The diagnosis of advanced or metastatic breast cancer has a devastating impact on patients, as well as their loved ones," said Paul Urick, Diplomat president. "KISQALI® is a groundbreaking new treatment that can improve quality of life for our patients."

According to the American Cancer Society, breast cancer is the second most common cancer among American women, with more than 315,000 diagnoses expected in 2017.

For full prescribing information, click here.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/diplomat-to-dispense-kisqali-for-metastatic-breast-cancer-300425161.html

SOURCE Diplomat Pharmacy, Inc.


-0.20 -0.95% $ 20.85 Volume: 243,772 Common Stock | 20 minute delay April 20, 2018

Investor Contact

Atul Kavthekar, CFO

Investor Relations,
Diplomat Pharmacy Inc.

Phone: 810.768.9380

Email Now